APO Research
Talk to an analyst

APO RESEARCH · REPORT

Opioid-Induced Constipation

Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.

Selected research

Market Outlook & Growth Opportunities

Global Opioid-Induced Constipation Market Outlook and Growth Opportunities 2026

21 December 2025195 pages

Choose your research edition.

Industry ResearchOpioid-Induced Constipation Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Opioid-Induced Constipation Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Opioid-Induced Constipation Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Opioid-Induced Constipation Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Opioid-Induced Constipation Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.

Global Opioid-Induced Constipation key players include Sanofi, Bayer, Purdue Pharm, etc. Global top three manufacturers hold a share over 45%.

North America is the largest market, with a share about 55%, followed by Europe, and Asia-Pacific, both have a share about 35 percent.

Read the full market overview

In terms of product, Lubiprostone is the largest segment, with a share about 5%. And in terms of application, the largest application is Pharmacy, followed by Hospital, etc.

This report provides an overview of the global Opioid-Induced Constipation market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Opioid-Induced Constipation and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Opioid-Induced Constipation sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Opioid-Induced Constipation market size, projected growth trends, production technologies, key applications, and end-use industries.

Opioid-Induced Constipation Segment by Company

Takeda Pharmaceuticals

Bayer

Sanofi

Mallinckrodt

Salix (Bausch Health)

AstraZeneca

Progenics Pharmaceuticals

Purdue Pharm

Nektar Therapeutics

Daiichi Sankyo

Prestige

GSK

Shionogi

Opioid-Induced Constipation Segment by Type

Methylnaltrexone Bromide

Lubiprostone

Naloxegol

Others

Opioid-Induced Constipation Segment by Application

Hospital

Pharmacy

Other

Opioid-Induced Constipation Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Opioid-Induced Constipation status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Opioid-Induced Constipation market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Opioid-Induced Constipation significant trends, drivers, influence factors in global and regions.

6. To analyze Opioid-Induced Constipation competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Opioid-Induced Constipation market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Opioid-Induced Constipation and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Opioid-Induced Constipation.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Opioid-Induced Constipation market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Opioid-Induced Constipation industry.

Chapter 3: Detailed analysis of Opioid-Induced Constipation manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Opioid-Induced Constipation in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Opioid-Induced Constipation in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Opioid-Induced Constipation Industry Trends Table 2. Opioid-Induced Constipation Industry Drivers Table 3. Opioid-Induced Constipation Industry Opportunities and Challenges Table 4. Opioid-Induced Constipation Industry Restraints Table 5. Global Opioid-Induced Constipation Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Opioid-Induced Constipation Revenue Share by Company (2021-2026) Table 7. Global Opioid-Induced Constipation Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Opioid-Induced Constipation Sales Volume Share by Company (2021-2026) Table 9. Global Opioid-Induced Constipation Average Price (USD/Unit) of Company (2021-2026) Table 10. Global Opioid-Induced Constipation Company Ranking, (2024-2026) & (USD Million) Table 11. Global Opioid-Induced Constipation Key Company Manufacturing Base & Headquarters Table 12. Global Opioid-Induced Constipation Company, Product Type & Application Table 13. Global Opioid-Induced Constipation Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Opioid-Induced Constipation by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Methylnaltrexone Bromide Table 18. Significant Companies of Lubiprostone Table 19. Significant Companies of Naloxegol Table 20. Significant Companies of Others Table 21. Global Opioid-Induced Constipation Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Opioid-Induced Constipation Sales Volume by Type (2021-2026) & (K Units) Table 23. Global Opioid-Induced Constipation Sales Volume by Type (2027-2032) & (K Units) Table 24. Global Opioid-Induced Constipation Sales Volume Share by Type (2021-2026) Table 25. Global Opioid-Induced Constipation Sales Volume Share by Type (2027-2032) Table 26. Global Opioid-Induced Constipation Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Opioid-Induced Constipation Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Opioid-Induced Constipation Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Opioid-Induced Constipation Sales Value Share by Type (2021-2026) Table 30. Global Opioid-Induced Constipation Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospital Table 32. Significant Companies of Pharmacy Table 33. Significant Companies of Other Table 34. Global Opioid-Induced Constipation Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Opioid-Induced Constipation Sales Volume by Application (2021-2026) & (K Units) Table 36. Global Opioid-Induced Constipation Sales Volume by Application (2027-2032) & (K Units) Table 37. Global Opioid-Induced Constipation Sales Volume Share by Application (2021-2026) Table 38. Global Opioid-Induced Constipation Sales Volume Share by Application (2027-2032) Table 39. Global Opioid-Induced Constipation Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Opioid-Induced Constipation Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Opioid-Induced Constipation Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Opioid-Induced Constipation Sales Value Share by Application (2021-2026) Table 43. Global Opioid-Induced Constipation Sales Value Share by Application (2027-2032) Table 44. Global Opioid-Induced Constipation Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Opioid-Induced Constipation Sales by Region (2021-2026) & (K Units) Table 46. Global Opioid-Induced Constipation Sales Market Share by Region (2021-2026) Table 47. Global Opioid-Induced Constipation Sales by Region (2027-2032) & (K Units) Table 48. Global Opioid-Induced Constipation Sales Market Share by Region (2027-2032) Table 49. Global Opioid-Induced Constipation Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Opioid-Induced Constipation Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Opioid-Induced Constipation Sales Value Share by Region (2021-2026) Table 52. Global Opioid-Induced Constipation Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Opioid-Induced Constipation Sales Value Share by Region (2027-2032) Table 54. Global Opioid-Induced Constipation Market Average Price (USD/Unit) by Region (2021-2026) Table 55. Global Opioid-Induced Constipation Market Average Price (USD/Unit) by Region (2027-2032) Table 56. Global Opioid-Induced Constipation Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global Opioid-Induced Constipation Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Opioid-Induced Constipation Sales by Country (2021-2026) & (K Units) Table 59. Global Opioid-Induced Constipation Sales Market Share by Country (2021-2026) Table 60. Global Opioid-Induced Constipation Sales by Country (2027-2032) & (K Units) Table 61. Global Opioid-Induced Constipation Sales Market Share by Country (2027-2032) Table 62. Global Opioid-Induced Constipation Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Opioid-Induced Constipation Sales Value Market Share by Country (2021-2026) Table 64. Global Opioid-Induced Constipation Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Opioid-Induced Constipation Sales Value Market Share by Country (2027-2032) Table 66. Takeda Pharmaceuticals Company Information Table 67. Takeda Pharmaceuticals Business Overview Table 68. Takeda Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 69. Takeda Pharmaceuticals Opioid-Induced Constipation Product Portfolio Table 70. Takeda Pharmaceuticals Recent Development Table 71. Bayer Company Information Table 72. Bayer Business Overview Table 73. Bayer Opioid-Induced Constipation Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 74. Bayer Opioid-Induced Constipation Product Portfolio Table 75. Bayer Recent Development Table 76. Sanofi Company Information Table 77. Sanofi Business Overview Table 78. Sanofi Opioid-Induced Constipation Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 79. Sanofi Opioid-Induced Constipation Product Portfolio Table 80. Sanofi Recent Development Table 81. Mallinckrodt Company Information Table 82. Mallinckrodt Business Overview Table 83. Mallinckrodt Opioid-Induced Constipation Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 84. Mallinckrodt Opioid-Induced Constipation Product Portfolio Table 85. Mallinckrodt Recent Development Table 86. Salix (Bausch Health) Company Information Table 87. Salix (Bausch Health) Business Overview Table 88. Salix (Bausch Health) Opioid-Induced Constipation Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 89. Salix (Bausch Health) Opioid-Induced Constipation Product Portfolio Table 90. Salix (Bausch Health) Recent Development Table 91. AstraZeneca Company Information Table 92. AstraZeneca Business Overview Table 93. AstraZeneca Opioid-Induced Constipation Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 94. AstraZeneca Opioid-Induced Constipation Product Portfolio Table 95. AstraZeneca Recent Development Table 96. Progenics Pharmaceuticals Company Information Table 97. Progenics Pharmaceuticals Business Overview Table 98. Progenics Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 99. Progenics Pharmaceuticals Opioid-Induced Constipation Product Portfolio Table 100. Progenics Pharmaceuticals Recent Development Table 101. Purdue Pharm Company Information Table 102. Purdue Pharm Business Overview Table 103. Purdue Pharm Opioid-Induced Constipation Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 104. Purdue Pharm Opioid-Induced Constipation Product Portfolio Table 105. Purdue Pharm Recent Development Table 106. Nektar Therapeutics Company Information Table 107. Nektar Therapeutics Business Overview Table 108. Nektar Therapeutics Opioid-Induced Constipation Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 109. Nektar Therapeutics Opioid-Induced Constipation Product Portfolio Table 110. Nektar Therapeutics Recent Development Table 111. Daiichi Sankyo Company Information Table 112. Daiichi Sankyo Business Overview Table 113. Daiichi Sankyo Opioid-Induced Constipation Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 114. Daiichi Sankyo Opioid-Induced Constipation Product Portfolio Table 115. Daiichi Sankyo Recent Development Table 116. Prestige Company Information Table 117. Prestige Business Overview Table 118. Prestige Opioid-Induced Constipation Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 119. Prestige Opioid-Induced Constipation Product Portfolio Table 120. Prestige Recent Development Table 121. GSK Company Information Table 122. GSK Business Overview Table 123. GSK Opioid-Induced Constipation Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 124. GSK Opioid-Induced Constipation Product Portfolio Table 125. GSK Recent Development Table 126. Shionogi Company Information Table 127. Shionogi Business Overview Table 128. Shionogi Opioid-Induced Constipation Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 129. Shionogi Opioid-Induced Constipation Product Portfolio Table 130. Shionogi Recent Development Table 131. Key Raw Materials Table 132. Raw Materials Key Suppliers Table 133. Opioid-Induced Constipation Distributors List Table 134. Opioid-Induced Constipation Customers List Table 135. Research Programs/Design for This Report Table 136. Authors List of This Report Table 137. Secondary Sources Table 138. Primary Sources List of Figures Figure 1. Opioid-Induced Constipation Product Image Figure 2. Global Opioid-Induced Constipation Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Opioid-Induced Constipation Sales Value (2021-2032) & (US$ Million) Figure 4. Global Opioid-Induced Constipation Sales (2021-2032) & (K Units) Figure 5. Global Opioid-Induced Constipation Sales Average Price (USD/Unit) & (2021-2032) Figure 6. Global Opioid-Induced Constipation Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Methylnaltrexone Bromide Image Figure 10. Lubiprostone Image Figure 11. Naloxegol Image Figure 12. Others Image Figure 13. Global Opioid-Induced Constipation Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Opioid-Induced Constipation Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Opioid-Induced Constipation Sales Volume Share by Type (2021-2032) Figure 16. Global Opioid-Induced Constipation Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Opioid-Induced Constipation Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Opioid-Induced Constipation Sales Value Share by Type (2021-2032) Figure 19. Hospital Image Figure 20. Pharmacy Image Figure 21. Other Image Figure 22. Global Opioid-Induced Constipation Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Opioid-Induced Constipation Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Opioid-Induced Constipation Sales Volume Share by Application (2021-2032) Figure 25. Global Opioid-Induced Constipation Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Opioid-Induced Constipation Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Opioid-Induced Constipation Sales Value Share by Application (2021-2032) Figure 28. Global Opioid-Induced Constipation Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global Opioid-Induced Constipation Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Opioid-Induced Constipation Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Opioid-Induced Constipation Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Opioid-Induced Constipation Sales Value (2021-2032) & (US$ Million) Figure 33. North America Opioid-Induced Constipation Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Opioid-Induced Constipation Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Opioid-Induced Constipation Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Opioid-Induced Constipation Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Opioid-Induced Constipation Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Opioid-Induced Constipation Sales Value (2021-2032) & (US$ Million) Figure 39. South America Opioid-Induced Constipation Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Opioid-Induced Constipation Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Opioid-Induced Constipation Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Opioid-Induced Constipation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Opioid-Induced Constipation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Opioid-Induced Constipation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Opioid-Induced Constipation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Opioid-Induced Constipation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Opioid-Induced Constipation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Opioid-Induced Constipation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Opioid-Induced Constipation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Opioid-Induced Constipation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Opioid-Induced Constipation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Opioid-Induced Constipation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Opioid-Induced Constipation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Opioid-Induced Constipation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Opioid-Induced Constipation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Opioid-Induced Constipation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Opioid-Induced Constipation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Opioid-Induced Constipation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Opioid-Induced Constipation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Opioid-Induced Constipation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Opioid-Induced Constipation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Opioid-Induced Constipation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Opioid-Induced Constipation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Opioid-Induced Constipation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Opioid-Induced Constipation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Opioid-Induced Constipation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Opioid-Induced Constipation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Opioid-Induced Constipation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Opioid-Induced Constipation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Opioid-Induced Constipation Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Opioid-Induced Constipation Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Methylnaltrexone Bromide
  • Lubiprostone
  • Naloxegol
  • Others
Applications
  • Hospital
  • Pharmacy
  • Other
Companies covered
  • Takeda Pharmaceuticals
  • Bayer
  • Sanofi
  • Mallinckrodt
  • Salix (Bausch Health)
  • AstraZeneca
  • Progenics Pharmaceuticals
  • Purdue Pharm
  • Nektar Therapeutics
  • Daiichi Sankyo
  • Prestige
  • GSK
  • Shionogi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Opioid-Induced Constipation Sales Value (2021-2032)
  4. 1.2.2 Global Opioid-Induced Constipation Sales Volume (2021-2032)
  5. 1.2.3 Global Opioid-Induced Constipation Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Opioid-Induced Constipation Market Dynamics
  1. 2.1 Opioid-Induced Constipation Industry Trends
  2. 2.2 Opioid-Induced Constipation Industry Drivers
  3. 2.3 Opioid-Induced Constipation Industry Opportunities and Challenges
  4. 2.4 Opioid-Induced Constipation Industry Restraints
3 Opioid-Induced Constipation Market by Company
  1. 3.1 Global Opioid-Induced Constipation Company Revenue Ranking in 2025
  2. 3.2 Global Opioid-Induced Constipation Revenue by Company (2021-2026)
  3. 3.3 Global Opioid-Induced Constipation Sales Volume by Company (2021-2026)
  4. 3.4 Global Opioid-Induced Constipation Average Price by Company (2021-2026)
  5. 3.5 Global Opioid-Induced Constipation Company Ranking (2024-2026)
  6. 3.6 Global Opioid-Induced Constipation Company Manufacturing Base and Headquarters
  7. 3.7 Global Opioid-Induced Constipation Company Product Type and Application
  8. 3.8 Global Opioid-Induced Constipation Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Opioid-Induced Constipation Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Opioid-Induced Constipation Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Opioid-Induced Constipation Market by Type
  1. 4.1 Opioid-Induced Constipation Type Introduction
  2. 4.1.1 Methylnaltrexone Bromide
  3. 4.1.2 Lubiprostone
  4. 4.1.3 Naloxegol
  5. 4.1.4 Others
  6. 4.2 Global Opioid-Induced Constipation Sales Volume by Type
  7. 4.2.1 Global Opioid-Induced Constipation Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Opioid-Induced Constipation Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Opioid-Induced Constipation Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Opioid-Induced Constipation Sales Value by Type
  11. 4.3.1 Global Opioid-Induced Constipation Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Opioid-Induced Constipation Sales Value by Type (2021-2032)
  13. 4.3.3 Global Opioid-Induced Constipation Sales Value Share by Type (2021-2032)
5 Opioid-Induced Constipation Market by Application
  1. 5.1 Opioid-Induced Constipation Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Opioid-Induced Constipation Sales Volume by Application
  6. 5.2.1 Global Opioid-Induced Constipation Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Opioid-Induced Constipation Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Opioid-Induced Constipation Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Opioid-Induced Constipation Sales Value by Application
  10. 5.3.1 Global Opioid-Induced Constipation Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Opioid-Induced Constipation Sales Value by Application (2021-2032)
  12. 5.3.3 Global Opioid-Induced Constipation Sales Value Share by Application (2021-2032)
6 Opioid-Induced Constipation Regional Sales and Value Analysis
  1. 6.1 Global Opioid-Induced Constipation Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Opioid-Induced Constipation Sales by Region (2021-2032)
  3. 6.2.1 Global Opioid-Induced Constipation Sales by Region: 2021-2026
  4. 6.2.2 Global Opioid-Induced Constipation Sales by Region (2027-2032)
  5. 6.3 Global Opioid-Induced Constipation Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Opioid-Induced Constipation Sales Value by Region (2021-2032)
  7. 6.4.1 Global Opioid-Induced Constipation Sales Value by Region: 2021-2026
  8. 6.4.2 Global Opioid-Induced Constipation Sales Value by Region (2027-2032)
  9. 6.5 Global Opioid-Induced Constipation Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Opioid-Induced Constipation Sales Value (2021-2032)
  12. 6.6.2 North America Opioid-Induced Constipation Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Opioid-Induced Constipation Sales Value (2021-2032)
  15. 6.7.2 Europe Opioid-Induced Constipation Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Opioid-Induced Constipation Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Opioid-Induced Constipation Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Opioid-Induced Constipation Sales Value (2021-2032)
  21. 6.9.2 South America Opioid-Induced Constipation Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Opioid-Induced Constipation Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Opioid-Induced Constipation Sales Value Share by Country, 2025 VS 2032
7 Opioid-Induced Constipation Country-level Sales and Value Analysis
  1. 7.1 Global Opioid-Induced Constipation Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Opioid-Induced Constipation Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Opioid-Induced Constipation Sales by Country (2021-2032)
  4. 7.3.1 Global Opioid-Induced Constipation Sales by Country (2021-2026)
  5. 7.3.2 Global Opioid-Induced Constipation Sales by Country (2027-2032)
  6. 7.4 Global Opioid-Induced Constipation Sales Value by Country (2021-2032)
  7. 7.4.1 Global Opioid-Induced Constipation Sales Value by Country (2021-2026)
  8. 7.4.2 Global Opioid-Induced Constipation Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Opioid-Induced Constipation Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Opioid-Induced Constipation Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Opioid-Induced Constipation Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Opioid-Induced Constipation Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Opioid-Induced Constipation Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Opioid-Induced Constipation Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Opioid-Induced Constipation Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Opioid-Induced Constipation Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Opioid-Induced Constipation Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Opioid-Induced Constipation Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Opioid-Induced Constipation Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Opioid-Induced Constipation Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Opioid-Induced Constipation Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Opioid-Induced Constipation Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Opioid-Induced Constipation Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Opioid-Induced Constipation Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Opioid-Induced Constipation Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Opioid-Induced Constipation Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Opioid-Induced Constipation Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Opioid-Induced Constipation Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Opioid-Induced Constipation Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Opioid-Induced Constipation Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Opioid-Induced Constipation Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Opioid-Induced Constipation Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Opioid-Induced Constipation Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Opioid-Induced Constipation Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Opioid-Induced Constipation Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Opioid-Induced Constipation Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Opioid-Induced Constipation Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Opioid-Induced Constipation Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceuticals
  2. 8.1.1 Takeda Pharmaceuticals Company Information
  3. 8.1.2 Takeda Pharmaceuticals Business Overview
  4. 8.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceuticals Opioid-Induced Constipation Product Portfolio
  6. 8.1.5 Takeda Pharmaceuticals Recent Developments
  7. 8.2 Bayer
  8. 8.2.1 Bayer Company Information
  9. 8.2.2 Bayer Business Overview
  10. 8.2.3 Bayer Opioid-Induced Constipation Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Bayer Opioid-Induced Constipation Product Portfolio
  12. 8.2.5 Bayer Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Opioid-Induced Constipation Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Opioid-Induced Constipation Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Mallinckrodt
  20. 8.4.1 Mallinckrodt Company Information
  21. 8.4.2 Mallinckrodt Business Overview
  22. 8.4.3 Mallinckrodt Opioid-Induced Constipation Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Mallinckrodt Opioid-Induced Constipation Product Portfolio
  24. 8.4.5 Mallinckrodt Recent Developments
  25. 8.5 Salix (Bausch Health)
  26. 8.5.1 Salix (Bausch Health) Company Information
  27. 8.5.2 Salix (Bausch Health) Business Overview
  28. 8.5.3 Salix (Bausch Health) Opioid-Induced Constipation Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Salix (Bausch Health) Opioid-Induced Constipation Product Portfolio
  30. 8.5.5 Salix (Bausch Health) Recent Developments
  31. 8.6 AstraZeneca
  32. 8.6.1 AstraZeneca Company Information
  33. 8.6.2 AstraZeneca Business Overview
  34. 8.6.3 AstraZeneca Opioid-Induced Constipation Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 AstraZeneca Opioid-Induced Constipation Product Portfolio
  36. 8.6.5 AstraZeneca Recent Developments
  37. 8.7 Progenics Pharmaceuticals
  38. 8.7.1 Progenics Pharmaceuticals Company Information
  39. 8.7.2 Progenics Pharmaceuticals Business Overview
  40. 8.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Progenics Pharmaceuticals Opioid-Induced Constipation Product Portfolio
  42. 8.7.5 Progenics Pharmaceuticals Recent Developments
  43. 8.8 Purdue Pharm
  44. 8.8.1 Purdue Pharm Company Information
  45. 8.8.2 Purdue Pharm Business Overview
  46. 8.8.3 Purdue Pharm Opioid-Induced Constipation Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Purdue Pharm Opioid-Induced Constipation Product Portfolio
  48. 8.8.5 Purdue Pharm Recent Developments
  49. 8.9 Nektar Therapeutics
  50. 8.9.1 Nektar Therapeutics Company Information
  51. 8.9.2 Nektar Therapeutics Business Overview
  52. 8.9.3 Nektar Therapeutics Opioid-Induced Constipation Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Nektar Therapeutics Opioid-Induced Constipation Product Portfolio
  54. 8.9.5 Nektar Therapeutics Recent Developments
  55. 8.10 Daiichi Sankyo
  56. 8.10.1 Daiichi Sankyo Company Information
  57. 8.10.2 Daiichi Sankyo Business Overview
  58. 8.10.3 Daiichi Sankyo Opioid-Induced Constipation Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Daiichi Sankyo Opioid-Induced Constipation Product Portfolio
  60. 8.10.5 Daiichi Sankyo Recent Developments
  61. 8.11 Prestige
  62. 8.11.1 Prestige Company Information
  63. 8.11.2 Prestige Business Overview
  64. 8.11.3 Prestige Opioid-Induced Constipation Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Prestige Opioid-Induced Constipation Product Portfolio
  66. 8.11.5 Prestige Recent Developments
  67. 8.12 GSK
  68. 8.12.1 GSK Company Information
  69. 8.12.2 GSK Business Overview
  70. 8.12.3 GSK Opioid-Induced Constipation Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 GSK Opioid-Induced Constipation Product Portfolio
  72. 8.12.5 GSK Recent Developments
  73. 8.13 Shionogi
  74. 8.13.1 Shionogi Company Information
  75. 8.13.2 Shionogi Business Overview
  76. 8.13.3 Shionogi Opioid-Induced Constipation Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Shionogi Opioid-Induced Constipation Product Portfolio
  78. 8.13.5 Shionogi Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Opioid-Induced Constipation Value Chain Analysis
  2. 9.1.1 Opioid-Induced Constipation Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Opioid-Induced Constipation Sales Mode & Process
  6. 9.2 Opioid-Induced Constipation Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Opioid-Induced Constipation Distributors
  9. 9.2.3 Opioid-Induced Constipation Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst